Molecular Partners AG American Depositary Shares (MOLN)
Stock · NASDAQ · Health Care
$3.56as of 10/16/2026
Price chart
Active signals
MOLN Signal Track Record
How signals performed across all stocks →What MOLN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 19 | +5.1% | 68% | September 14, 2026 |
| Bollinger Band Breakout | 19 | -7.6% | 32% | August 27, 2026 |
| 200-Day Moving Average TouchActive now | 14 | +1.5% | 57% | September 18, 2026 |
| Volume Spike | 9 | -0.5% | 33% | April 28, 2025 |
| Any 20-session window (baseline) | -1.9% | 42% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MOLN
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloi…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 134
- Website
- www.molecularpartners.com/
Fundamentals
- 1-day range
- $3.52$3.7
- Market cap
- $163.47M
- P/E (trailing)
- —
- P/E (forward)
- -21.61
- EPS (trailing)
- $-1.37
- Dividend yield
- —
- Beta
- 0.22
- Avg. volume
- 1.3K
Forecasts
5 analyst ratings
Molecular Partners AG American Depositary Shares Competitors
Chosen by industry and closest market cap.
- MOLNMolecular Partners AG American Depositary Shares$3.56▼ 2.47%Market cap $163.47MP/E —$2.66$3.96
- LENZLENZ Therapeutics Inc. Common Stock$3.27▼ 8.40%Market cap $163.67MP/E —$3.35$42.98
- CRBUCaribou Biosciences Inc. Common Stock$0.47▲ 1.08%Market cap $162.66MP/E —$0.4425$3.54
- ABOSAcumen Pharmaceuticals Inc. Common Stock$1.69▲ 1.20%Market cap $164.68MP/E —$1.5$3.6
- IPHAInnate Pharma S.A. ADS$1.43▼ 3.38%Market cap $167.42MP/E —$1.03$2.33
- HUMAHumacyte Inc. Common Stock$0.429▼ 2.50%Market cap $157.54MP/E —$0.337$1.9
- TNYATenaya Therapeutics Inc. Common Stock$0.381▼ 6.62%Market cap $157.50MP/E —$0.3601$2.04
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MOLN Molecular Partners AG American Depositary Shares | $163.47M | — | $3.56 | ▼ 2.47% | $2.66$3.96 |
| LENZ LENZ Therapeutics Inc. Common Stock | $163.67M | — | $3.27 | ▼ 8.40% | $3.35$42.98 |
| CRBU Caribou Biosciences Inc. Common Stock | $162.66M | — | $0.47 | ▲ 1.08% | $0.4425$3.54 |
| ABOS Acumen Pharmaceuticals Inc. Common Stock | $164.68M | — | $1.69 | ▲ 1.20% | $1.5$3.6 |
| IPHA Innate Pharma S.A. ADS | $167.42M | — | $1.43 | ▼ 3.38% | $1.03$2.33 |
| HUMA Humacyte Inc. Common Stock | $157.54M | — | $0.429 | ▼ 2.50% | $0.337$1.9 |
| TNYA Tenaya Therapeutics Inc. Common Stock | $157.50M | — | $0.381 | ▼ 6.62% | $0.3601$2.04 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 3.59M
- Total value held
- $14.24M
- Institutional holders
- 4
- Unknown2.22M
- Unknown1.35M
- Unknown15.5K
- Unknown367
See the full, filterable feed with live charts on the MarketWall dashboard.